Budget Impact Analysis of Botulinum Toxin Type A Treatment for Cerebral Palsy In The Russian Federation

Abstract

Objectives: To conduct budget impact analysis of abobotulinumtoxinA+standard therapy, onabotulinumtoxinA+standard therapy and standard therapy solely in patients with spastic cerebral palsy (SCP) in Russia for 2-year period. Total number of patients with spastic cerebral palsy in Russia is 55 899. Methods: A budget impact model was developed in Excel 2013 to simulate the costs of spastic cerebral palsy therapy in the Russian Federation. The following costs were taken into account: the costs of pharmacotherapy, inpatient and outpatient, sanatorium-resort care, costs of adverse events, casting, orthopedic surgeons, disability pensions, disable child care benefit. Costs of pharmacotherapy were taken from the essential drug list and the database of drugs prices. Standard of treatment of CP developed by Ministry of Health of the Russian Federation was used for calculation of medical care costs. Costs of adverse events were calculated basing on Russian clinical guidelines and database of drugs prices. Disability pensions and disable child care were taken from the Russian Pension Fund database. The cost of orthopedic surgeries was calculated on the basis of RF Government program of state guarantees of free rendering to citizens of medical care. Results: Usage of AbobotulinumtoxinA treatment+standard therapy in whole population of SCP patients in Russia will result in 79,585 RUB/1,473 $ economy compared with OnabotulinumtoxinA+standard therapy, 131,178 RUB/2,429 $ economy compared with standard therapy per one patient for 2 years. This cost reduction is mainly attributed to decrease of number of orthopedic surgeries to the better efficacy of this BTA drug. Conclusions: Inclusion of abobotulinumtoxinA+standard therapy appears to be a cost saving treatment option in the management of spastic cerebral palsy in the Russian Federation compared with onabotulinumtoxinA+standard therapy and standard therapy solely.